<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 4, 1996
ImmuLogic Pharmaceutical Corporation
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-19117 13-3397957
- ------------------------ -------------------
(Commission File Number) (I.R.S. Employer
Identification No.)
610 Lincoln Street
Waltham, Massachusetts 02154
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(617) 466-6000
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
Not Applicable
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Page 1 of 6 Pages
Exhibit Index is on Page 4
<PAGE> 2
Item 5. Other Events.
- ----------------------
On December 4, 1996, the Company announced the appointment of Dr. Joseph
Marr, M.D., Executive Vice President of Research and Development/Chief
Scientific Officer, to the additional position of acting President and Chief
Executive Officer. Dr. Marr succeeds Robert J. Gerety, following Dr. Gerety's
resignation on December 4, 1996, from the position of President and Chief
Executive Officer and Director of the Company.
In addition, Richard N. Small, Vice President and Chief Financial Officer
of the Company has accepted a position as Senior Vice President and Chief
Financial Officer at Immune Therapeutics Inc., a start-up biotechnology company
in Massachusetts. However, at the request of the Board of Directors, Rich Small
has postponed his departure to remain in his current position as Vice President
and Chief Financial Officer through a transition period.
Item 7. Financial Statements and Exhibits.
- -------------------------------------------
Exhibit
No. Description
- ------- -----------
99.1 Press Release dated December 4, 1996.
- 2 -
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: December 13, 1996 IMMULOGIC PHARMACEUTICAL CORPORATION
/s/ Richard N. Small
----------------------------------------
By: Richard N. Small,
Title: Vice President and
Chief Financial Officer
- 3 -
<PAGE> 4
Exhibit Index
-------------
Exhibit No. Exhibit
- ----------- -------
99.1 Press Release, dated December 4, 1996
- 4 -
<PAGE> 1
FOR IMMEDIATE RELEASE
CONTACT: SUSAN PRIMROSE - DIRECTOR OF INVESTOR RELATIONS
IMMULOGIC PHARMACEUTICAL CORP.
617/466-6000
IMMULOGIC ANNOUNCES MANAGEMENT CHANGES
Waltham, MA December 04, 1996 --- ImmuLogic Pharmaceutical Corporation (NASDAQ:
IMUL) today announced the appointment of Dr. Joseph Marr, M.D., currently
Executive Vice President of Research and Development/Chief Scientific Officer,
to the additional position of acting President and Chief Executive Officer. Dr.
Marr succeeds Robert J. Gerety, following Dr. Gerety's resignation, today, from
the position of President and Chief Executive Officer and Director of the
company.
In addition, Richard N. Small, Vice President and Chief Financial Officer
has accepted a position as Senior Vice President and Chief Financial Officer at
Immune Therapeutics Inc., a start-up biotechnology company in Massachusetts.
However, at the request of the Board of Directors, Rich Small has postponed his
departure to remain in his current position as Vice President and Chief
Financial Officer through a transition period.
"Dr. Marr has the confidence and support of the Board to lead ImmuLogic
toward commercialization of our products in development," said Malcolm Gefter,
Ph.D., Chairman of the Board. "Dr. Marr's academic and pharmaceutical experience
combined with his leadership and management skills qualify him to move the
company into its next phase of development."
Dr. Marr's career encompasses more than twenty five years of academic
medicine, basic and clinical research, and industry research and development
experience. Prior to joining ImmuLogic in July 1996 as Executive Vice President
of Research/Chief
Page 1 of 2
<PAGE> 2
Scientific Officer, Dr. Marr was Vice President, Research and Development at
Ribozyme Pharmaceuticals from 1993 to 1996. He joined Ribozyme at the formative
stage and played an integral part in building the scientific and development
programs and taking the company public. In addition, he helped establish three
corporate partnerships with pharmaceutical firms during his tenure. From 1989 to
1993, Dr. Marr was Senior Vice President, Discovery Research at Searle Research
and Development where he managed a group of 240 scientists. Dr. Marr also was a
consultant with the World Health Organization from 1982 to 1992 during which
time he designed and implemented certain late stage clinical trials for WHO.
From 1970 to 1989, Dr. Marr held academic positions including Vice Chairman,
Department of Medicine, Director Division of Infectious Diseases and Professor
of Medicine and Biochemistry. He received his MD from the Johns Hopkins
University School of Medicine.
Dr. Marr commented, "Our immediate focus is the completion of discussions
with the FDA regarding the development of the ALLERVAX[Registered Trademark]
CAT product, to complete the data analyses of the recently finished ragweed
trial and report these results in the first quarter of 1997, and to file an
Investigational New Drug (IND) application to begin clinical trials for our
multiple sclerosis therapeutic. In addition, a major goal is to choose the
strategy by which to commercialize our allergy therapeutics; discussions with
potential commercial partners continue at this time.
"Our longer vision calls for ImmuLogic to generate significant revenues
from the ALLERVAX[Registered Trademark] CAT and ALLERVAX[Registered Trademark]
RAGWEED products and to advance multiple product candidates from the allergy,
autoimmune, and drugs of abuse programs to later stage clinical development."
ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company,
located in Waltham, Massachusetts, with the primary goal of developing peptide
therapeutics to treat allergies and autoimmune diseases. The Company also is
developing a poison ivy/poison oak therapeutic and a vaccine to treat cocaine
abuse.
Page 2 of 2
